Skip to main
CLPT
CLPT logo

CLPT Stock Forecast & Price Target

CLPT Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ClearPoint Neuro Inc. is positioned for a strong future, demonstrating a solid foundation with a reported 17% topline growth in 2023, alongside a significant reduction in cash burn. The company is expected to see at least 20% revenue growth in 2024, driven by an expanding partnership base and enhanced service offerings in its Biologics division. Additionally, the momentum gained in 2024 through key product approvals and record system installations showcases ClearPoint Neuro's ability to innovate and capture market share, further supporting a favorable outlook for the company's financial prospects.

Bears say

ClearPoint Neuro Inc has demonstrated a significant reduction in cash burn, decreasing from $5.8 million in the first quarter of 2023 to $1.2 million in the fourth quarter, indicating improved financial management. However, despite this positive trend in cash burn, the overall financial health remains a concern due to the company's reliance on this singular metric without substantial revenue growth reported to ensure sustainability. Furthermore, the company's ongoing need to further decrease cash burn in 2024 raises questions about its operational viability and ability to invest in future growth initiatives.

CLPT has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clearpoint Neuro Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clearpoint Neuro Inc (CLPT) Forecast

Analysts have given CLPT a Strong Buy based on their latest research and market trends.

According to 3 analysts, CLPT has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clearpoint Neuro Inc (CLPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.